Related Experiment Videos
Pathologic hyperprolactinemia
1Center for Endocrinology, Metabolism, and Nutrition, Northwestern University Medical School, Chicago, Illinois.
Endocrinology and Metabolism Clinics of North America
|December 1, 1992
Summary
Prolactin (PRL) is regulated by the hypothalamus and can increase due to various factors, including medications and tumors. Treatment for hyperprolactinemia often involves dopamine agonists or surgery.
Area of Science:
- Endocrinology
- Neuroendocrinology
- Pituitary Gland Physiology
Background:
- Prolactin (PRL) secretion is uniquely under tonic hypothalamic inhibition, primarily via dopamine.
- Factors influencing PRL levels include sleep, meals, pregnancy, and suckling.
- Dysregulation can stem from medications, systemic diseases, hypothalamic lesions, or prolactinomas.
Purpose of the Study:
- To provide a comprehensive overview of prolactin regulation, secretion, and pathophysiology.
- To discuss the causes and diagnostic approaches to hyperprolactinemia.
- To outline current treatment strategies for prolactinomas and related conditions.
Main Methods:
- Review of existing literature on prolactin physiology and pathology.
- Analysis of diagnostic testing protocols including routine chemistry, thyroid function, and imaging (MRI/CT).
- Evaluation of therapeutic interventions such as dopamine agonists, surgery, and radiotherapy.
Main Results:
- Hyperprolactinemia can result from hypothalamic dysregulation, structural lesions, or prolactinomas.
- Diagnostic workup involves biochemical tests and pituitary imaging.
- Dopamine agonists are the primary treatment for prolactinomas, with surgery as an alternative.
Conclusions:
- Understanding prolactin regulation is crucial for diagnosing and managing hyperprolactinemia.
- Treatment choice depends on tumor size, patient response, and reproductive goals.
- While effective, long-term cure rates vary, especially for macroadenomas.